Evidence map›Paper›PMID 42399829›Full record

ArticleBMC cancer2026

Preliminary study on the mechanism of OPN up-regulating PD-L1 to induce CD8 + T cell exhaustion in synovial sarcoma.

Huifang Zhuo, Xinyi Li, Zhongxu Xue, Wenyu An, Lian Meng, Wei Jia, Ning Wang

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huifang Zhuo *Department of Pathology, Department of Pathology, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi University, Xinjiang, 832002, China.
Xinyi Li *Department of Pathology, Department of Pathology, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi University, Xinjiang, 832002, China.
Zhongxu XueDepartment of Pathology, Department of Pathology, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi University, Xinjiang, 832002, China.
Wenyu AnDepartment of Pathology, Department of Pathology, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi University, Xinjiang, 832002, China.
Lian MengDepartment of Pathology, Department of Pathology, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi University, Xinjiang, 832002, China.
Wei JiaDepartment of Pathology, Department of Pathology, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi University, Xinjiang, 832002, China. jiawei@shzu.edu.cn.
Ning WangDepartment of Pathology, Department of Pathology, the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi University, Xinjiang, 832002, China. wangning_729@126.com.ORCID http://orcid.org/0000-0001-9114-7603

Funding

National Natural Science Foundation of China 82002846
6 · The paper itself

Abstract

backgroundSynovial sarcoma (SS) is a rare and highly malignant soft tissue sarcoma. The efficacy of existing therapies is limited, and new strategies are urgently needed. Osteopontin (OPN) promotes disease progression by regulating tumor-immune cell interaction and immunosuppressive microenvironment, which is a potential therapeutic target. The aim of this study was to investigate the role of OPN in SS immune regulation and tumor progression.

methodsA stable cell line with OPN knockdown was constructed using lentiviral transduction. RNA-seq and bioinformatics analysis were used to predict the correlation between OPN and immunity. Flow cytometry and ELISA were used to detect the changes in the number and function of CD8 + T cells. EDU, CCK-8 and Transwell chamber experiments were used to detect the proliferation, invasion and migration ability of SS. The protein interaction between OPN and PD-L1 was detected by molecular docking and Co-IP. The expression of PD-L1 was detected by Western blot and flow cytometry. The expression levels of OPN, PD-L1 and CD8 were detected by immunohistochemistry. To predict the correlation of OPN, PD-L1 and CD8 in sarcoma tissues and their clinical prognostic significance.

resultsRNA-seq analysis revealed that OPN-associated differentially expressed genes were significantly enriched in immune response-related biological processes. Bioinformatics analysis demonstrated that OPN expression in sarcoma was associated with immune responses and T-cell activation, and was negatively correlated with immune cell infiltration. OPN induced CD8⁺ T-cell exhaustion, thereby promoting immune evasion and facilitating the proliferation, invasion, and migration of synovial sarcoma (SS) cells. Molecular docking and co-immunoprecipitation assays confirmed a direct protein-protein interaction between OPN and PD-L1, and knockdown of OPN resulted in a significant reduction in PD-L1 expression. In SS tissues, OPN was highly expressed, whereas PD-L1 and CD8 were expressed at low levels and exhibited a positive correlation. Furthermore, bioinformatics analysis showed that PD-L1 expression was positively correlated with CD8 expression in sarcoma, and low CD8 expression was associated with poor prognosis.

conclusionsWe preliminarily propose that OPN promotes immune evasion in synovial sarcoma (SS) by regulating PD-L1 expression and subsequently inducing CD8⁺ T-cell exhaustion. This mechanism suggests that OPN may serve as a novel immunotherapeutic target and provides new insights into the development of immunotherapy strategies for SS.

Indexed as

B7-H1 AntigenCD8-Positive T-LymphocytesOsteopontinSarcoma, SynovialCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMolecular Docking SimulationPrognosisT-Cell ExhaustionTumor MicroenvironmentUp-RegulationB7-H1 AntigenCD274 protein, humanOsteopontinSPP1 protein, humanCD8 + T cellsEscape of immunityOPNPD-L1Synovial sarcoma

Identifiers

PMID42399829
PMCPMC13632446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.